Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 58 entries
Sorted by: Best Match Show Resources per page
[Drop in suicide rate after first psychosis: a comparison with the situation two decades ago].

Nederlands tijdschrift voor geneeskunde

Castelein S, Liemburg EJ, de Lange JS, van Es F, Visser E, Aleman A, Bruggemans R, Knegtering H.
PMID: 26732214
Ned Tijdschr Geneeskd. 2015;159:A9565.

OBJECTIVE: Over two decades ago a study reported that a percentage as high as 11% of the patients with a psychotic disorder in the northern Netherlands died by committing suicide. The primary objective of the current study was to...

Cite
Castelein S, Liemburg EJ, de Lange JS, et al. Daling suïcidecijfer na eerste psychose: een vergelijking met de situatie van twee decennia terug. [Drop in suicide rate after first psychosis: a comparison with the situation two decades ago]. Ned Tijdschr Geneeskd. 2015;159:A9565
Castelein, S., Liemburg, E. J., de Lange, J. S., van Es, F., Visser, E., Aleman, A., Bruggemans, R., & Knegtering, H. (2015). Daling suïcidecijfer na eerste psychose: een vergelijking met de situatie van twee decennia terug. [Drop in suicide rate after first psychosis: a comparison with the situation two decades ago]. Nederlands tijdschrift voor geneeskunde, 159A9565.
Castelein, Stynke, et al. "Daling suïcidecijfer na eerste psychose: een vergelijking met de situatie van twee decennia terug." [Drop in suicide rate after first psychosis: a comparison with the situation two decades ago]. Nederlands tijdschrift voor geneeskunde vol. 159 (2015): A9565.
Castelein S, Liemburg EJ, de Lange JS, van Es F, Visser E, Aleman A, Bruggemans R, Knegtering H. Daling suïcidecijfer na eerste psychose: een vergelijking met de situatie van twee decennia terug. [Drop in suicide rate after first psychosis: a comparison with the situation two decades ago]. Ned Tijdschr Geneeskd. 2015;159:A9565. Dutch. PMID: 26732214.
Copy Download .nbib Format: NLM
Aspirin chemoprevention for colorectal cancer: helpful, harmful, or still too soon to tell?.

Gastroenterology

Limburg PJ, Cerhan JR.
PMID: 17681190
Gastroenterology. 2007 Aug;133(2):717-8. doi: 10.1053/j.gastro.2007.06.040.

No abstract available.

Cite
Limburg PJ, Cerhan JR. Aspirin chemoprevention for colorectal cancer: helpful, harmful, or still too soon to tell?. Gastroenterology. 2007;133(2):717-8doi: 10.1053/j.gastro.2007.06.040.
Limburg, P. J., & Cerhan, J. R. (2007). Aspirin chemoprevention for colorectal cancer: helpful, harmful, or still too soon to tell?. Gastroenterology, 133(2), 717-8. https://doi.org/10.1053/j.gastro.2007.06.040
Limburg, Paul J, and Cerhan, James R. "Aspirin chemoprevention for colorectal cancer: helpful, harmful, or still too soon to tell?." Gastroenterology vol. 133,2 (2007): 717-8. doi: https://doi.org/10.1053/j.gastro.2007.06.040
Limburg PJ, Cerhan JR. Aspirin chemoprevention for colorectal cancer: helpful, harmful, or still too soon to tell?. Gastroenterology. 2007 Aug;133(2):717-8. doi: 10.1053/j.gastro.2007.06.040. PMID: 17681190.
Copy Download .nbib Format: NLM
Do hollow atoms exist in front of an insulating LiF(100) surface?.

Physical review letters

Aumayr F, Hoekstra R, Kurz H, Limburg J, Morgenstern R, Schippers S, Winter H.
PMID: 10059638
Phys Rev Lett. 1995 Jul 10;75(2):217-219. doi: 10.1103/PhysRevLett.75.217.

No abstract available.

Cite
Aumayr F, Hoekstra R, Kurz H, et al. Do hollow atoms exist in front of an insulating LiF(100) surface?. Phys Rev Lett. 1995;75(2):217-219doi: 10.1103/PhysRevLett.75.217.
Aumayr, F., Hoekstra, R., Kurz, H., Limburg, J., Morgenstern, R., Schippers, S., & Winter, H. (1995). Do hollow atoms exist in front of an insulating LiF(100) surface?. Physical review letters, 75(2), 217-219. https://doi.org/10.1103/PhysRevLett.75.217
Aumayr, et al. "Do hollow atoms exist in front of an insulating LiF(100) surface?." Physical review letters vol. 75,2 (1995): 217-219. doi: https://doi.org/10.1103/PhysRevLett.75.217
Aumayr F, Hoekstra R, Kurz H, Limburg J, Morgenstern R, Schippers S, Winter H. Do hollow atoms exist in front of an insulating LiF(100) surface?. Phys Rev Lett. 1995 Jul 10;75(2):217-219. doi: 10.1103/PhysRevLett.75.217. PMID: 10059638.
Copy Download .nbib Format: NLM
AACR Cancer Progress Report 2014.

Clinical cancer research : an official journal of the American Association for Cancer Research

Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ.
PMID: 25228531
Clin Cancer Res. 2014 Oct 01;20(19):S1-S112. doi: 10.1158/1078-0432.CCR-14-2123. Epub 2014 Sep 16.

No abstract available.

Cite
Arteaga CL, Adamson PC, Engelman JA, et al. AACR Cancer Progress Report 2014. Clin Cancer Res. 2014;20(19):S1-S112doi: 10.1158/1078-0432.CCR-14-2123.
Arteaga, C. L., Adamson, P. C., Engelman, J. A., Foti, M., Gaynor, R. B., Hilsenbeck, S. G., Limburg, P. J., Lowe, S. W., Mardis, E. R., Ramsey, S., Rebbeck, T. R., Richardson, A. L., Rubin, E. H., & Weiner, G. J. (2014). AACR Cancer Progress Report 2014. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(19), S1-S112. https://doi.org/10.1158/1078-0432.CCR-14-2123
Arteaga, Carlos L, et al. "AACR Cancer Progress Report 2014." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 20,19 (2014): S1-S112. doi: https://doi.org/10.1158/1078-0432.CCR-14-2123
Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ. AACR Cancer Progress Report 2014. Clin Cancer Res. 2014 Oct 01;20(19):S1-S112. doi: 10.1158/1078-0432.CCR-14-2123. Epub 2014 Sep 16. PMID: 25228531; PMCID: PMC4666597.
Copy Download .nbib Format: NLM
Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use.

Mayo Clinic proceedings

Finney Rutten LJ, Parks PD, Weiser E, Fan C, Jacobson DJ, Jenkins GD, Zhu X, Griffin JM, Limburg PJ.
PMID: 34920895
Mayo Clin Proc. 2022 Jan;97(1):101-109. doi: 10.1016/j.mayocp.2021.06.028. Epub 2021 Dec 14.

OBJECTIVE: To assess health care provider (HCP) preferences related to colorectal cancer (CRC) screening overall, and by HCP and patient characteristics.PARTICIPANTS AND METHODS: We developed a survey based on the Theoretical Domains Framework to assess factors associated with CRC...

Cite
Finney Rutten LJ, Parks PD, Weiser E, et al. Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use. Mayo Clin Proc. 2021;97(1):101-109doi: 10.1016/j.mayocp.2021.06.028.
Finney Rutten, L. J., Parks, P. D., Weiser, E., Fan, C., Jacobson, D. J., Jenkins, G. D., Zhu, X., Griffin, J. M., & Limburg, P. J. (2022). Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use. Mayo Clinic proceedings, 97(1), 101-109. https://doi.org/10.1016/j.mayocp.2021.06.028
Finney Rutten, Lila J, et al. "Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use." Mayo Clinic proceedings vol. 97,1 (2022): 101-109. doi: https://doi.org/10.1016/j.mayocp.2021.06.028
Finney Rutten LJ, Parks PD, Weiser E, Fan C, Jacobson DJ, Jenkins GD, Zhu X, Griffin JM, Limburg PJ. Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use. Mayo Clin Proc. 2022 Jan;97(1):101-109. doi: 10.1016/j.mayocp.2021.06.028. Epub 2021 Dec 14. PMID: 34920895.
Copy Download .nbib Format: NLM
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.

JAMA psychiatry

Merritt K, McGuire PK, Egerton A, Aleman A, Block W, Bloemen OJN, Borgan F, Bustillo JR, Capizzano AA, Coughlin JM, De la Fuente-Sandoval C, Demjaha A, Dempster K, Do KQ, Du F, Falkai P, Galinska-Skok B, Gallinat J, Gasparovic C, Ginestet CE, Goto N, Graff-Guerrero A, Ho BC, Howes OD, Jauhar S, Jeon P, Kato T, Kaufmann CA, Kegeles LS, Keshavan M, Kim SY, Kunugi H, Lauriello J, Liemburg EJ, Mcilwain ME, Modinos G, Mouchlianitis ED, Nakamura J, Nenadic I, Öngür D, Ota M, Palaniyappan L, Pantelis C, Plitman E, Posporelis S, Purdon SE, Reichenbach JR, Renshaw PF, Russell BR, Sawa A, Schaefer M, Shungu DC, Smesny S, Stanley JA, Stone JM, Szulc A, Taylor R, Thakkar K, Théberge J, Tibbo PG, van Amelsvoort T, Walecki J, Williamson PC, Wood SJ, Xin L, Yamasue H.
PMID: 33881460
JAMA Psychiatry. 2021 Jun 01;78(6):667-681. doi: 10.1001/jamapsychiatry.2021.0380.

IMPORTANCE: Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered brain glutamatergic function may be associated with the pathophysiology of schizophrenia and the response to antipsychotic treatment. However, the association of altered glutamatergic function with clinical and demographic factors...

Cite
Merritt K, McGuire PK, Egerton A. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data. JAMA Psychiatry. 2021;78(6):667-681doi: 10.1001/jamapsychiatry.2021.0380.
Merritt, K., McGuire, P. K., Egerton, A., Aleman, A., Block, W., Bloemen, O. J. N., Borgan, F., Bustillo, J. R., Capizzano, A. A., Coughlin, J. M., De la Fuente-Sandoval, C., Demjaha, A., Dempster, K., Do, K. Q., Du, F., Falkai, P., Galinska-Skok, B., Gallinat, J., Gasparovic, C., Ginestet, C. E., Goto, N., Graff-Guerrero, A., Ho, B. C., Howes, O. D., Jauhar, S., Jeon, P., Kato, T., Kaufmann, C. A., Kegeles, L. S., Keshavan, M., Kim, S. Y., Kunugi, H., Lauriello, J., Liemburg, E. J., Mcilwain, M. E., Modinos, G., Mouchlianitis, E. D., Nakamura, J., Nenadic, I., Öngür, D., Ota, M., Palaniyappan, L., Pantelis, C., Plitman, E., Posporelis, S., Purdon, S. E., Reichenbach, J. R., Renshaw, P. F., Russell, B. R., Sawa, A., Schaefer, M., Shungu, D. C., Smesny, S., Stanley, J. A., Stone, J. M., Szulc, A., Taylor, R., Thakkar, K., Théberge, J., Tibbo, P. G., van Amelsvoort, T., Walecki, J., Williamson, P. C., Wood, S. J., Xin, L., & Yamasue, H. (2021). Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data. JAMA psychiatry, 78(6), 667-681. https://doi.org/10.1001/jamapsychiatry.2021.0380
Merritt, Kate, et al. "Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data." JAMA psychiatry vol. 78,6 (2021): 667-681. doi: https://doi.org/10.1001/jamapsychiatry.2021.0380
Merritt K, McGuire PK, Egerton A, Aleman A, Block W, Bloemen OJN, Borgan F, Bustillo JR, Capizzano AA, Coughlin JM, De la Fuente-Sandoval C, Demjaha A, Dempster K, Do KQ, Du F, Falkai P, Galinska-Skok B, Gallinat J, Gasparovic C, Ginestet CE, Goto N, Graff-Guerrero A, Ho BC, Howes OD, Jauhar S, Jeon P, Kato T, Kaufmann CA, Kegeles LS, Keshavan M, Kim SY, Kunugi H, Lauriello J, Liemburg EJ, Mcilwain ME, Modinos G, Mouchlianitis ED, Nakamura J, Nenadic I, Öngür D, Ota M, Palaniyappan L, Pantelis C, Plitman E, Posporelis S, Purdon SE, Reichenbach JR, Renshaw PF, Russell BR, Sawa A, Schaefer M, Shungu DC, Smesny S, Stanley JA, Stone JM, Szulc A, Taylor R, Thakkar K, Théberge J, Tibbo PG, van Amelsvoort T, Walecki J, Williamson PC, Wood SJ, Xin L, Yamasue H. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data. JAMA Psychiatry. 2021 Jun 01;78(6):667-681. doi: 10.1001/jamapsychiatry.2021.0380. PMID: 33881460; PMCID: PMC8060889.
Copy Download .nbib Format: NLM
Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.

Cancer biology & therapy

Weinberg DS, Foster NR, Della'Zanna G, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Henry CH, Moleski SM, Limburg PJ, Waldman SA.
PMID: 34632925
Cancer Biol Ther. 2021 Dec 02;22(10):544-553. doi: 10.1080/15384047.2021.1967036. Epub 2021 Oct 10.

Guanylyl cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of the luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention...

Cite
Weinberg DS, Foster NR, Della'Zanna G, et al. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021;22(10):544-553doi: 10.1080/15384047.2021.1967036.
Weinberg, D. S., Foster, N. R., Della'Zanna, G., McMurray, R. P., Kraft, W. K., Pallotto, A., Kastenberg, D. M., Katz, L. C., Henry, C. H., Moleski, S. M., Limburg, P. J., & Waldman, S. A. (2021). Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer biology & therapy, 22(10), 544-553. https://doi.org/10.1080/15384047.2021.1967036
Weinberg, David S, et al. "Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers." Cancer biology & therapy vol. 22,10 (2021): 544-553. doi: https://doi.org/10.1080/15384047.2021.1967036
Weinberg DS, Foster NR, Della'Zanna G, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Henry CH, Moleski SM, Limburg PJ, Waldman SA. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021 Dec 02;22(10):544-553. doi: 10.1080/15384047.2021.1967036. Epub 2021 Oct 10. PMID: 34632925.
Copy Download .nbib Format: NLM
Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy.

Implementation science communications

Zhu X, Lee MK, Weiser E, Griffin JM, Limburg PJ, Finney Rutten LJ.
PMID: 34666841
Implement Sci Commun. 2021 Oct 19;2(1):119. doi: 10.1186/s43058-021-00221-x.

BACKGROUND: Colorectal cancer (CRC) screening for average risk adults age 45 and older continues to be underutilized in the USA. One factor consistently associated with CRC screening completion is clinician recommendation. Understanding the barriers and facilitators of clinical adoption...

Cite
Zhu X, Lee MK, Weiser E, et al. Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy. Implement Sci Commun. 2021;2(1):119doi: 10.1186/s43058-021-00221-x.
Zhu, X., Lee, M. K., Weiser, E., Griffin, J. M., Limburg, P. J., & Finney Rutten, L. J. (2021). Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy. Implementation science communications, 2(1), 119. https://doi.org/10.1186/s43058-021-00221-x
Zhu, Xuan, et al. "Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy." Implementation science communications vol. 2,1 (2021): 119. doi: https://doi.org/10.1186/s43058-021-00221-x
Zhu X, Lee MK, Weiser E, Griffin JM, Limburg PJ, Finney Rutten LJ. Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy. Implement Sci Commun. 2021 Oct 19;2(1):119. doi: 10.1186/s43058-021-00221-x. PMID: 34666841; PMCID: PMC8527805.
Copy Download .nbib Format: NLM
Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.

Cancer biology & therapy

Weinberg DS, Foster NR, Della'Zanna G, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Henry CH, Moleski SM, Limburg PJ, Waldman SA.
PMID: 34632925
Cancer Biol Ther. 2021 Oct 10;1-10. doi: 10.1080/15384047.2021.1967036. Epub 2021 Oct 10.

Guanylyl cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of the luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention...

Cite
Weinberg DS, Foster NR, Della'Zanna G, et al. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021;1-10doi: 10.1080/15384047.2021.1967036.
Weinberg, D. S., Foster, N. R., Della'Zanna, G., McMurray, R. P., Kraft, W. K., Pallotto, A., Kastenberg, D. M., Katz, L. C., Henry, C. H., Moleski, S. M., Limburg, P. J., & Waldman, S. A. (2021). Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer biology & therapy, 1-10. https://doi.org/10.1080/15384047.2021.1967036
Weinberg, David S, et al. "Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers." Cancer biology & therapy vol. (2021): 1-10. doi: https://doi.org/10.1080/15384047.2021.1967036
Weinberg DS, Foster NR, Della'Zanna G, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Henry CH, Moleski SM, Limburg PJ, Waldman SA. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021 Oct 10;1-10. doi: 10.1080/15384047.2021.1967036. Epub 2021 Oct 10. PMID: 34632925.
Copy Download .nbib Format: NLM
Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.

Cancer biology & therapy

Weinberg DS, Foster NR, Della'Zanna G, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Henry CH, Moleski SM, Limburg PJ, Waldman SA.
PMID: 34632925
Cancer Biol Ther. 2021 Dec 02;22(10):544-553. doi: 10.1080/15384047.2021.1967036. Epub 2021 Oct 10.

Guanylyl cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of the luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention...

Cite
Weinberg DS, Foster NR, Della'Zanna G, et al. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021;22(10):544-553doi: 10.1080/15384047.2021.1967036.
Weinberg, D. S., Foster, N. R., Della'Zanna, G., McMurray, R. P., Kraft, W. K., Pallotto, A., Kastenberg, D. M., Katz, L. C., Henry, C. H., Moleski, S. M., Limburg, P. J., & Waldman, S. A. (2021). Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer biology & therapy, 22(10), 544-553. https://doi.org/10.1080/15384047.2021.1967036
Weinberg, David S, et al. "Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers." Cancer biology & therapy vol. 22,10 (2021): 544-553. doi: https://doi.org/10.1080/15384047.2021.1967036
Weinberg DS, Foster NR, Della'Zanna G, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Henry CH, Moleski SM, Limburg PJ, Waldman SA. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021 Dec 02;22(10):544-553. doi: 10.1080/15384047.2021.1967036. Epub 2021 Oct 10. PMID: 34632925; PMCID: PMC8726613.
Copy Download .nbib Format: NLM
A Worksite Wellness Intervention: Improving Happiness, Life Satisfaction, and Gratitude in Health Care Workers.

Mayo Clinic proceedings. Innovations, quality & outcomes

Berkland BE, Werneburg BL, Jenkins SM, Friend JL, Clark MM, Rosedahl JK, Limburg PJ, Riley BA, Lecy DR, Sood A.
PMID: 30225418
Mayo Clin Proc Innov Qual Outcomes. 2017 Oct 31;1(3):203-210. doi: 10.1016/j.mayocpiqo.2017.09.002. eCollection 2017 Dec.

OBJECTIVE: To assess the effect of a 12-week Stress Management and Resilience Training (SMART) program on happiness, life satisfaction, gratitude, mindfulness, spirituality, and stress in health care workers.PARTICIPANTS AND METHODS: Participants were members of an employee wellness center at...

Cite
Berkland BE, Werneburg BL, Jenkins SM, et al. A Worksite Wellness Intervention: Improving Happiness, Life Satisfaction, and Gratitude in Health Care Workers. Mayo Clin Proc Innov Qual Outcomes. 2017;1(3):203-210doi: 10.1016/j.mayocpiqo.2017.09.002.
Berkland, B. E., Werneburg, B. L., Jenkins, S. M., Friend, J. L., Clark, M. M., Rosedahl, J. K., Limburg, P. J., Riley, B. A., Lecy, D. R., & Sood, A. (2017). A Worksite Wellness Intervention: Improving Happiness, Life Satisfaction, and Gratitude in Health Care Workers. Mayo Clinic proceedings. Innovations, quality & outcomes, 1(3), 203-210. https://doi.org/10.1016/j.mayocpiqo.2017.09.002
Berkland, Bridget E, et al. "A Worksite Wellness Intervention: Improving Happiness, Life Satisfaction, and Gratitude in Health Care Workers." Mayo Clinic proceedings. Innovations, quality & outcomes vol. 1,3 (2017): 203-210. doi: https://doi.org/10.1016/j.mayocpiqo.2017.09.002
Berkland BE, Werneburg BL, Jenkins SM, Friend JL, Clark MM, Rosedahl JK, Limburg PJ, Riley BA, Lecy DR, Sood A. A Worksite Wellness Intervention: Improving Happiness, Life Satisfaction, and Gratitude in Health Care Workers. Mayo Clin Proc Innov Qual Outcomes. 2017 Oct 31;1(3):203-210. doi: 10.1016/j.mayocpiqo.2017.09.002. eCollection 2017 Dec. PMID: 30225418; PMCID: PMC6132199.
Copy Download .nbib Format: NLM
A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience.

Global advances in health and medicine

Rieck TM, Lee JR, Ferguson JA, Peterson LA, Martin Lillie CM, Clark MM, Limburg PJ, Bauer BA.
PMID: 31827983
Glob Adv Health Med. 2019 Nov 29;8:2164956119892597. doi: 10.1177/2164956119892597. eCollection 2019.

OBJECTIVES: The aim of this study was to compare the stress reduction effects of spending 25 minutes reclining in a SolTec™ Lounge between 2 intervention groups. Group 1 experienced the Lounge with multilayered music on an external speaker, while...

Cite
Rieck TM, Lee JR, Ferguson JA, et al. A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience. Glob Adv Health Med. 2019;8:2164956119892597doi: 10.1177/2164956119892597.
Rieck, T. M., Lee, J. R., Ferguson, J. A., Peterson, L. A., Martin Lillie, C. M., Clark, M. M., Limburg, P. J., & Bauer, B. A. (2019). A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience. Global advances in health and medicine, 82164956119892597. https://doi.org/10.1177/2164956119892597
Rieck, Thomas M, et al. "A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience." Global advances in health and medicine vol. 8 (2019): 2164956119892597. doi: https://doi.org/10.1177/2164956119892597
Rieck TM, Lee JR, Ferguson JA, Peterson LA, Martin Lillie CM, Clark MM, Limburg PJ, Bauer BA. A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience. Glob Adv Health Med. 2019 Nov 29;8:2164956119892597. doi: 10.1177/2164956119892597. eCollection 2019. PMID: 31827983; PMCID: PMC6886274.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 58 entries